{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=10", "query": { "condition": "Control Subjects", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 5448, "total_pages": 545, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T19:41:20.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01940159", "title": "A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SEP-363856", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2013-08", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 2, "location_summary": "Glendale, California • Long Beach, California", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940159" }, { "nct_id": "NCT02972840", "title": "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Mantle Cell" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 635, "start_date": "2017-04-05", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 32, "location_summary": "Tucson, Arizona • Downey, California • Santa Monica, California + 27 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972840" }, { "nct_id": "NCT00249782", "title": "A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rosacea" ], "interventions": [ { "name": "Vehicle control, 2x/day", "type": "DRUG" }, { "name": "ACZONE (dapsone) Gel, 5%, 2x/day", "type": "DRUG" }, { "name": "ACZONE (dapsone) Gel, 5%, 1x/day", "type": "DRUG" }, { "name": "MetroGel® (metronidazole gel), 1.0% 1x/day", "type": "DRUG" }, { "name": "ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2005-11", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2011-05-30", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249782" }, { "nct_id": "NCT02993523", "title": "A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 443, "start_date": "2017-02-02", "completion_date": "2026-06-15", "has_results": true, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 24, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 17 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993523" }, { "nct_id": "NCT00627640", "title": "Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Parkinson's Disease" ], "interventions": [ { "name": "Safinimide 50-100 mg/day", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newron Pharmaceuticals SPA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 549, "start_date": "2009-02", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-03-29", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627640" }, { "nct_id": "NCT01631474", "title": "A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "CB-03-01", "type": "DRUG" }, { "name": "Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intrepid Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 363, "start_date": "2012-06", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2020-11-16", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 13, "location_summary": "Los Angeles, California • San Diego, California • Sanford, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sanford", "state": "Florida" }, { "city": "Snellville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01631474" }, { "nct_id": "NCT01007097", "title": "Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "TAK-875", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 426, "start_date": "2009-12", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2016-04-13", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007097" }, { "nct_id": "NCT05494697", "title": "Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Rintatolimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AIM ImmunoTech Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2027-08", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Canton, Ohio • Seattle, Washington", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Canton", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05494697" }, { "nct_id": "NCT02735603", "title": "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Heart Repolarization" ], "interventions": [ { "name": "Naltrexone HCl/bupropion HCl", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Orexigen Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 84, "start_date": "2016-04", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-11-01", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735603" }, { "nct_id": "NCT01694485", "title": "Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Abrilumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 359, "start_date": "2012-11-16", "completion_date": "2018-04-10", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-10-19T19:41:20.767Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01694485" } ] }